Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 4Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 17Lymphoid 8Myeloid 3Tumor-Agnostic 2Plasma cell 2Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 488Lymphoma, T-Cell, Cutaneous 92Carcinoma, Non-Small-Cell Lung 89Mycosis Fungoides 72Neoplasm Metastasis 71Skin Neoplasms 62Neoplasms 61Sezary Syndrome 60Carcinoma, Renal Cell 60Lymphoma, Non-Hodgkin 53Lymphoma, Large B-Cell, Diffuse 53Lymphoma 53Breast Neoplasms 52Leukemia, Lymphocytic, Chronic, B-Cell 50Lymphoma, Follicular 47Lymphoma, Mantle-Cell 46Lymphoma, B-Cell, Marginal Zone 46Squamous Cell Carcinoma of Head and Neck 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 44Hodgkin Disease 44Colorectal Neoplasms 43Burkitt Lymphoma 43Lymphoma, Large-Cell, Immunoblastic 41Ovarian Neoplasms 38Multiple Myeloma 35Uveal Melanoma 34Leukemia, Hairy Cell 33Lymphoma, Large-Cell, Anaplastic 32Sarcoma 31Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 31

Interventions

Cyclophosphamide 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasm, Residual × Dermatologic × Clear all
NCT02054104 2022-01-26

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
21 enrolled 11 charts
DermatologicSarcoma

Melanoma, Sarcoma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡